Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA4 | P22748 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2010947 | 0.98 | TSHR (0.50) | TSHRLMNAALDH1A1ESR2PTGS2 | |
| SCHEMBL14152352 | 0.98 | TSHR (0.50) | TSHRLMNAALDH1A1ESR2PTGS2 | |
| SCHEMBL2009498 | 0.98 | TSHR (0.50) | TSHRLMNAALDH1A1ESR2PTGS2 | |
| SCHEMBL2010998 | 0.98 | TSHR (0.50) | TSHRLMNAALDH1A1ESR2PTGS2 | |
| SCHEMBL2016061 | 0.98 | TSHR (0.50) | TSHRLMNAALDH1A1ESR2PTGS2 | |
| SCHEMBL2012153 | 0.98 | TSHR (0.50) | TSHRLMNAALDH1A1ESR2PTGS2 | |
| SCHEMBL2013628 | 0.94 | TSHR (0.54) | TSHRLMNAALDH1A1ESR2PTGS2 | |
| SCHEMBL2011016 | 0.86 | TSHR (0.50) | TSHRLMNAALDH1A1CA12 | |
| SCHEMBL2012707 | 0.81 | CYP1A2 (0.48) | TSHRALDH1A1ESR2PTGS2CA12 | |
| SCHEMBL10063280 | 0.81 | CA12 (0.44) | ALDH1A1ESR2PTGS2CA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260125379-A1 | PRODRUG OF JAK KINASE INHIBITOR | E NITIATE BIOPHARMACEUTICALS HANGZHOU CO LTD (CN) | 2026-05-07 | — | — | US | disclosed |
| EP-4582425-A1 | PRODRUG OF JAK KINASE INHIBITOR | E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd (CN) | 2025-07-09 | — | — | EP | disclosed |
| US-9365489-B2 | Nitrooxy alkanoic acids and derivatives thereof in feed for reducing methane emission in ruminants, and/or to improve ruminant performance | DSM IP ASSETS B.V. (NL) | 2016-06-14 | — | — | US | disclosed |
| US-8784871-B2 | Nitrooxy alkanoic acids and derivatives thereof in feed for reducing methane emission in ruminants, and/or to improve ruminant performance | DSM IP ASSETS B.V. (NL) | 2014-07-22 | — | — | US | disclosed |
| US-20140134282-A1 | NITROOXY ALKANOIC ACIDS AND DERIVATIVES THEREOF IN FEED FOR REDUCING METHANE EMISSION IN RUMINANTS, AND/OR TO IMPROVE RUMINANT PERFORMANCE | DSM IP ASSETS B.V. (NL) | 2014-05-15 | — | — | US | disclosed |
| EP-2509435-B1 | NITROOXY ALKANOIC ACIDS AND DERIVATIVES THEREOF IN FEED FOR REDUCING METHANE EMISSION IN RUMINANTS, AND/OR TO IMPROVE RUMINANT PERFORMANCE | DSM IP ASSETS BV (NL) | 2014-02-26 | — | — | EP | disclosed |
| US-20120315339-A1 | NITROOXY ALKANOIC ACIDS AND DERIVATIVES THEREOF IN FEED FOR REDUCING METHANE EMISSION IN RUMINANTS, AND/OR TO IMPROVE RUMINANT PERFORMANCE | DSM IP ASSETS B.V. (NL) | 2012-12-13 | — | — | US | disclosed |
| EP-2509435-A1 | NITROOXY ALKANOIC ACIDS AND DERIVATIVES THEREOF IN FEED FOR REDUCING METHANE EMISSION IN RUMINANTS, AND/OR TO IMPROVE RUMINANT PERFORMANCE | DSM IP Assets B.V. (NL) | 2012-10-17 | — | — | EP | disclosed |
| WO-2011070133-A1 | NITROOXY ALKANOIC ACIDS AND DERIVATIVES THEREOF IN FEED FOR REDUCING METHANE EMISSION IN RUMINANTS, AND/OR TO IMPROVE RUMINANT PERFORMANCE | DSM IP ASSETS B.V. (NL) | 2011-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140134282-A1 | NITROOXY ALKANOIC ACIDS AND DERIVATIVES THEREOF IN FEED FOR REDUCING METHANE EMISSION IN RUMINANTS, AND/OR TO IMPROVE RUMINANT PERFORMANCE | PIGS, TECR, CYP4X1 | TSHR 630/4885LMNA 901/4885ALDH1A1 2126/4885 |
| US-20120315339-A1 | NITROOXY ALKANOIC ACIDS AND DERIVATIVES THEREOF IN FEED FOR REDUCING METHANE EMISSION IN RUMINANTS, AND/OR TO IMPROVE RUMINANT PERFORMANCE | PIGS, TECR, CYP4X1 | TSHR 630/4885LMNA 901/4885ALDH1A1 2126/4885 |
| US-20260125379-A1 | PRODRUG OF JAK KINASE INHIBITOR | JAK1, JAK2, JAK3 | TSHR 519/4885LMNA 2664/4885ALDH1A1 1710/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.